Retatrutide vs Tirzepatide
A side-by-side research comparison of Retatrutide and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Retatrutide | Tirzepatide |
|---|---|---|
| Full name | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | FDA Approved |
| Mechanism | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | 5,200 Da (approximate) | 4,814 Da |
| Half-life | 6 days | 5 days (120 hours) |
| Bioavailability | High (SubQ) | High (SubQ ~80%) |
| Typical dose | 1-2 mg → titrate up to 12 mg | 2.5 mg → titrate up to 15 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.